VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
2.770
+0.070 (2.59%)
At close: Jan 21, 2025, 4:00 PM
2.900
+0.130 (4.70%)
After-hours: Jan 21, 2025, 6:13 PM EST
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 2 or -16.67% compared to the previous year.
Employees
10
Change (1Y)
-2
Growth (1Y)
-16.67%
Revenue / Employee
$49,300
Profits / Employee
-$3,414,900
Market Cap
40.86M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
VYNE News
- 15 days ago - VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - GlobeNewsWire
- 4 weeks ago - VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 5 months ago - VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 - GlobeNewsWire
- 9 months ago - VYNE Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire